Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02502006 · ClinicalTrials.gov registry record · Phase 1

Variability in Response to Non-steroidal Anti-inflammatory Drugs

A Phase 1 study, sponsored by University of Pennsylvania.

Terminated
Registry status
Phase 1
Development phase
16
Enrollment target

NCT02502006: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.

NCT02502006 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02502006, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability.

Primary Outcome

COX-1 activity was measured ex vivo using a whole blood assay. Thromboxane A2 serum concentrations were quantified before, and 0.5, 1, 2, 4, 8, and 12 h after treatment and expressed as AUC over the 12 hour dosing interval.

Interventions

  • DRUG Placebo
  • DRUG Celecoxib
  • DRUG Naproxen

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2015-11
Est. Completion 2022-09
Phase Phase 1
University of Pennsylvania

1,423 total trials

Why NCT02502006 stopped before completion

NCT02502006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02502006 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02502006 about?

NCT02502006 is a clinical study titled "Variability in Response to Non-steroidal Anti-inflammatory Drugs". This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability.

What is the current status of trial NCT02502006?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-11. Estimated completion is 2022-09.

What interventions are being tested in trial NCT02502006?

The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Naproxen (DRUG).

Who is sponsoring clinical trial NCT02502006?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02502006's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02502006, the US trial registry maintained by the National Library of Medicine. NCT02502006 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.